Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections

被引:26
作者
Capitano, B
Nicolau, DR
Potoski, BA
Byers, KE
Horowitz, M
Venkataramanan, R
Paterson, DL
机构
[1] Univ Pittsburgh, Ctr Med, Antibiot Management Program, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Ctr Med, Dept Pharm & Therapeut, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Ctr Med, Div Infect Dis, Pittsburgh, PA 15260 USA
[4] Univ Pittsburgh, Ctr Med, Dept Neurosurg, Pittsburgh, PA 15260 USA
[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA
[6] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA
[7] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06115 USA
来源
PHARMACOTHERAPY | 2004年 / 24卷 / 06期
关键词
meropenem; central nervous system; gram-negative central nervous system infection; antibiotic resistance; antibiotic management; pharmacodynamics; pharmacokinetics; meningitis;
D O I
10.1592/phco.24.8.803.36070
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment of gram-negative infection of the central nervous system (CNS) presents a clinical challenge due to antibiotic resistance and difficulties with penetration into the cerebrospinal fluid (CSF). Two patients with gram-negative CNS infections were treated successfully with high-dose, prolonged infusions of meropenem. The CSF meropenem concentrations exceeded the minimum inhibitory concentration of the pathogen for virtually the entire dosing interval in both cases. Our experience demonstrates that dosage modification to maximize pharmacodynamic targets and bactericidal activity may be practically applied to optimize antibiotic treatment for difficult-to-treat CNS infections.
引用
收藏
页码:803 / 807
页数:5
相关论文
共 19 条
[1]  
*ASTR PHARM, 2001, MERR MER PROD INF
[2]   MEROPENEM TREATMENT OF POSTTRAUMATIC MENINGITIS DUE TO PSEUDOMONAS-AERUGINOSA [J].
CHMELIK, V ;
GUTVIRTH, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (06) :922-923
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[5]   PENETRATION OF MEROPENEM INTO THE CEREBROSPINAL-FLUID OF PATIENTS WITH INFLAMED MENINGES [J].
DAGAN, R ;
VELGHE, L ;
RODDA, JL ;
KLUGMAN, KP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 (01) :175-179
[6]   Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion [J].
Dandekar, PK ;
Maglio, D ;
Sutherland, CA ;
Nightingale, CH ;
Nicolau, DP .
PHARMACOTHERAPY, 2003, 23 (08) :988-991
[7]  
DONNELLY JP, 1992, LANCET, V339, P1117
[8]   High-performance liquid chromatographic assay for meropenem in serum [J].
Elkhaili, H ;
Niedergang, S ;
Pompei, D ;
Linger, L ;
Leveque, D ;
Jehl, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1996, 686 (01) :19-26
[9]  
Federico G, 2001, SCAND J INFECT DIS, V33, P533, DOI 10.1080/00365540110026557
[10]   RANDOMIZED COMPARISON OF MEROPENEM WITH CEFOTAXIME FOR TREATMENT OF BACTERIAL-MENINGITIS [J].
KLUGMAN, KP ;
DAGAN, R ;
WILLIAMS, KJ ;
FEATHERSTONE, A ;
BEATTY, D ;
LEARY, M ;
WALKER, K ;
RODDA, J ;
SCHER, G ;
HOUSEHAM, C ;
PELSAR, H ;
LOPEZ, E ;
FALLO, L ;
TREGNAGHI, MW ;
AIRD, A ;
DEAPRA, EQ ;
BEGUE, P ;
BOULESTEIX, J ;
FLORET, D ;
ASTRUC, J ;
BOUILLE, C ;
CARRIERE, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1140-1146